Artal Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,024,226
| Closed | -$114M | – | 118 |
|
|
2023
Q3 | $88.2M | Sell |
2,024,226
-30,955
| -2% | -$1.11M | 3.78% | 3 |
|
|
2023
Q2 | $74.3M | Buy |
2,055,181
+517,472
| +34% | +$21.3M | 2.3% | 6 |
|
|
2023
Q1 | $57.2M | Sell |
1,537,709
-295,049
| -16% | -$13.3M | 3.4% | 7 |
|
|
2022
Q4 | $83M | Buy |
1,832,758
+507,758
| +38% | +$32.9M | 4.64% | 3 |
|
|
2022
Q3 | $92.5M | Buy |
1,325,000
+225,000
| +20% | +$16.6M | 3.95% | 3 |
|
|
2022
Q2 | $73.8M | Sell |
1,100,000
-250,000
| -19% | -$15.9M | 3.94% | 7 |
|
|
2022
Q1 | $111M | Sell |
1,350,000
-50,000
| -4% | -$5.11M | 4.65% | 5 |
|
|
2021
Q4 | $205M | Buy |
1,400,000
+200,000
| +17% | +$31.1M | 5.57% | 3 |
|
|
2021
Q3 | $212M | Buy |
1,200,000
+350,000
| +41% | +$56.3M | 4.75% | 4 |
|
|
2021
Q2 | $137M | Buy |
850,000
+125,000
| +17% | +$20.1M | 2.79% | 8 |
|
|
2021
Q1 | $124M | Buy |
725,000
+225,000
| +45% | +$44.5M | 2.19% | 9 |
|
|
2020
Q4 | $110M | Hold |
500,000
| – | – | 2.36% | 7 |
|
|
2020
Q3 | $83M | Buy |
+500,000
| New | +$68.4M | 2.02% | 13 |
|
|
2019
Q4 | – | Sell |
-200,000
| Closed | -$15.6M | – | 110 |
|
|
2019
Q3 | $15.6M | Buy |
200,000
+50,000
| +33% | +$4.69M | 0.62% | 32 |
|
|
2019
Q2 | $15.4M | Sell |
150,000
-25,000
| -14% | -$1.95M | 0.62% | 37 |
|
|
2019
Q1 | $12.8M | Buy |
+175,000
| New | +$11.9M | 0.52% | 43 |
|
|
2018
Q1 | – | Sell |
-100,000
| Closed | -$1.82M | – | 137 |
|
|
2017
Q4 | $1.82M | Buy |
+100,000
| New | +$1.55M | 0.03% | 98 |
|
|
2015
Q3 | – | Sell |
-61,276
| Closed | -$1.93M | – | 87 |
|
|
2015
Q2 | $1.93M | Sell |
61,276
-188,724
| -75% | -$5.56M | 0.08% | 68 |
|
|
2015
Q1 | $7.33M | Hold |
250,000
| – | – | 0.34% | 51 |
|
|
2014
Q4 | $4.63M | Hold |
250,000
| – | – | 0.16% | 69 |
|
|
2014
Q3 | $4.38M | Hold |
250,000
| – | – | 0.16% | 63 |
|
|
2014
Q2 | $5M | Hold |
250,000
| – | – | 0.2% | 67 |
|
|
2014
Q1 | $4.77M | Buy |
250,000
+75,000
| +43% | +$1.56M | 0.17% | 73 |
|
|
2013
Q4 | $2.91M | Buy |
+175,000
| New | +$2.99M | 0.1% | 74 |
|
Other funds holding MRTX
Artal Group's MRTX Position: Q4 2023 in Review
Artal Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 2,024,226 shares — an estimated $114M sold.
Artal Group first reported a position in MRTX in Q4 2013 and held it in 24 quarters. The position peaked at $212M in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.
- Artal Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Artal Group sold 2,024,226 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $114M.
- Artal Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 24 quarters.
- Artal Group's Mirati Therapeutics, Inc. Common Stock position peaked at $212M in Q3 2021.
- 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.
Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.